Description du projet
Le complexe I comme cible critique dans la guérison des maladies mitochondriales
Les mitochondries sont les plaques tournantes de l’énergie cellulaire, générant la majorité de l’adénosine 5′-triphosphate (ATP) cellulaire via une chaîne respiratoire couplée à la phosphorylation oxydative. L’oxydation du nicotinamide adénine dinucléotide + hydrogène (NADH) par l’enzyme NADH:ubiquinone oxydoréductase (complexe I) constitue la principale force motrice de la synthèse de l’ATP. La déficience du complexe I constitue la pathologie la plus courante dans les maladies mitochondriales, la maladie de Parkinson, le diabète, le cancer et le vieillissement. Des données préliminaires ont démontré que la stabilisation du complexe I était susceptible d’améliorer les symptômes de la déficience respiratoire dans des modèles cellulaires de dysfonctionnement mitochondrial, et que cette stabilisation pouvait être obtenue par la perte de la peptidase caséinolytique. Le projet CICURE, financé par l’UE, vise à étudier la possibilité de cibler la peptidase caséinolytique située dans la matrice mitochondriale pour améliorer les symptômes des maladies mitochondriales en utilisant des modèles génétiques in vivo.
Objectif
Mitochondria are found within every human cell and are responsible for the majority of energy production in the cell. When the mitochondria do not function properly, they cause devastating diseases affecting many and often multiple organs with the highest energy needs, such as skeletal muscle, brain, heart and liver. Over the years we have steadily increased our understanding of the genetic and molecular mechanisms leading to mitochondrial disease, developed different models and biomarkers. Unfortunately, development of effective therapeutic approaches able to improve the outcome of the diseases or at least to ameliorate or postpone the symptoms was much less effective.
Today, therapeutic options for mitochondrial diseases still remain focused on supportive dietary interventions aimed at relieving complications. Therefore, it would be ideal if a single approach could be developed that would be equally effective with various mitochondrial diseases most often characterized by complex I deficiency.
Our preliminary data show that by removing the major mitochondrial matrix protease CLPXP, and therefore stabilizing CI, we could ameliorate the symptoms of respiratory deficiency in different cellular models of mitochondrial dysfunction. The loss of CLPP in these models resulted not only in increased stability of CI, but also normalized NAD+/ NADH that collectively resulted in improved proliferation and survival rates. Remarkably, even partial loss of ClpXP activity in respiratory deficient cells led to mild increase in the CI levels, opening an exciting prospect for therapeutic interventions. Therefore, the overall goal of this project is to explore the possibility of targeting CLPP activity to ameliorate symptoms of mitochondrial diseases in in vivo models through genetic interventions and search for specific protease inhibitors.
Programme(s)
Appel à propositions
(s’ouvre dans une nouvelle fenêtre) ERC-2018-PoC
Voir d’autres projets de cet appelRégime de financement
ERC-POC - Proof of Concept GrantInstitution d’accueil
50937 Koeln
Allemagne